Eli Lilly nears $1.3 billion deal for gene-editing biotech Verve Therapeutics, FT reports
(Reuters) -Eli Lilly is in advanced talks to acquire gene editing startup Verve Therapeutics for up to $1.3 billion, aiming ...
Read moreDetailsTag: gene therapy
Bluebird bio receives higher upfront offer from PE firms Carlyle, SK Capital
(Reuters) -Bluebird bio and Carlyle Group and SK Capital Partners said on Wednesday that the private equity firms have offered ...
Read moreDetailsChina’s WuXi to sell Advanced Therapies unit to US private equity firm
(Reuters) - China's WuXi AppTec said on Tuesday its subsidiaries have signed a deal with U.S.-based private equity firm Altaris ...
Read moreDetails
